Thomas J. Herzfeld Advisors, Inc. Incyte Corp Transaction History

Thomas J. Herzfeld Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $13,980 - $15,955	242 New	242 $14 Million
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $1,437 - $1,575	-18 Reduced 6.92%	242 $20,000
Q3 2020 Nov 12, 2020	SELL	$85.07 - $109.69 $510 - $658	-6 Reduced 2.26%	260 $23,000
Q2 2020 Aug 12, 2020	BUY	$74.18 - $108.93 $1,780 - $2,614	24 Added 9.92%	266 $26,000
Q2 2017 Aug 14, 2017	BUY	N/A	242	242 $30,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Thomas J. Herzfeld Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Thomas J. Herzfeld Advisors, Inc. with notifications on news.